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Introduction 
1.1 Neuronal Ceroid Lipofuscinoses 
The neuronal ceroid lipofuscinoses (NCLs) are a heterogeneous group of 
progressive neurodegenerative disorders affecting children and adults, 
characterized by retinopathy leading to blindness, ataxia and gait 
abnormalities, drug-resistant progressive myoclonic epilepsy, mental 
deterioration, and an early death. NCL diseases were classiﬁed according to 
the age at disease onset (congenital, infantile, late infantile, juvenile, adult). 
The NCLs have a worldwide distribution and are usually transmitted 
according to an autosomal-recessive pattern of inheritance. Fourteen 
different forms of NCL have been described to date, classified according to 
the designation of the mutated gene (CLN) and over 400 mutations have 
been identified (www.ucl.ac.uk/ncl/mutation). Many of the genes that 
cause typical NCL disease with onset in childhood have been  identiﬁed 
and in very recent years the genetic basis of many of the later onset cases 
has been delineated, including the dominant adult onset NCL disease. More 
NCL genes remain to be identiﬁed as in some patients mutations cannot be 
demonstrated in any of the known NCL genes although they present with 
the typical NCL symptoms and characteristic lysosomal storage material 
(Tab.1). 
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Human neuronal ceroid lipofuscinoses variants 
Disease Eponym OMIM Clinical phenotype Gene Protein 
CLN1 Haltia–Santavuori 256730 
Classic infantile, late 
infantile, juvenile, 
adult* 
CLN1 (PPT1) PPT‐1 
CLN2 
Janský–
Bielschowsky 
204500 
Classic late infantile, 
juvenile* 
CLN2 (TPP1) TPP‐1 
CLN3 Spielmeyer–Sjögren 204200 Juvenile* CLN3 
CLN3 protein 
(battenin) 
CLN4 Parry 162350 
Adult autosomal 
dominant* 
CLN4 
(DNAJC5) 
DnaJ homologue 
subfamily C 
member 
CLN5 
Finnish variant late 
infantile, variant 
juvenile (previously 
CLN9) 
256731 
Late infantile variant, 
juvenile, adult* 
CLN5 Protein CLN5 
CLN6 
Early juvenile (Lake 
Cavanaugh), late 
infantile Costa 
Rican‐Indian 
variant, adult Kuf 
type A 
601780 
Late infantile variant, 
adult* (Kuf, type A)* 
CLN6 Protein CLN6 
CLN7 
Turkish variant late 
infantile 
610951 
Late infantile variant*, 
juvenile*, adult* 
CLN7 
(MFSD8) 
Major facilitator 
superfamily 
domain‐containing 
protein 
CLN8 
Northern epilepsy, 
progressive EPMR 
610003 
Late infantile variant 
EPMR* 
CLN8 Protein CLN8 
CLN10 Congenital 610127 
Congenital classic*, 
late infantile*, adult* 
CLN10 
(CTSD) 
Cathepsin D 
CLN11 Adult variant — Adult* CLN11 (GRN) Progranulin 
CLN12 Juvenile variant — 
Juvenile, Kufor–
Rakeb syndrome* 
CLN12 
(ATP13A2) 
— 
CLN13 Adult Kuf type B — Adult Kuf type* 
CLN13 
(CTSF) 
Cathepsin F 
CLN14 Infantile — 
Infantile, progressive 
myoclonus epilepsy 
3* 
CLN14 
(KCTD7) 
Potassium channel 
tetramerization 
domain‐ containing 
protein 
*These diseases have neurological involvement. Abbreviation: EPMR, epilepsy with mental retardation. 
Table1. Human ceroid lipofuscinoses variants (Boustany et al., 2013). 
 
They are considered lysosomal storage disorders (LSD), because of their 
characteristic accumulation of autofluorescent ceroid lipopigments, subunit 
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c of mitochondrial ATP synthase and/or the sphingolipid activator proteins 
saponins A and D (SAPs) in lysosomes of most cells, including neurons, 
skin fibroblasts and blood lymphocytes. Immunohistochemistry reveals the 
presence of abundant sphingolipid activator proteins (SAPs) in CLN1 and 
CLN10 whilst subunit C of mitochondrial ATP synthase (SCMAS) prevails 
in the lipopigments of other CLN forms. A minor component of either 
SAPs or SCMAS may also be encountered in the forms of CLN where the 
other component dominates the picture (Anderson et al., 2013). The 
various NCLs are characterized by electrondense ultrastructural features 
that are unique to each disorder, described as curvilinear (CV), rectilinear 
(RL), fingerprint (FP) or granular osmiophilic deposit (GROD) profiles, 
and the aberrant storage is accompanied by neuronal death and cerebral 
and/or cerebellar cortical atrophy (Anderson et al., 2013). 
NCL-causing mutated proteins (CLN1 to CLN14) represent soluble 
lysosomal enzymes, polytopic membrane proteins which localize to the 
endoplasmic reticulum or to the endosomal/lysosomal compartment and 
directly or indirectly regulate lysosomal function (Fig.1). Although the 
precise function of most of the NCL proteins remains elusive. Despite the 
identiﬁcation of several disease causing genes and many studies of the 
respective NCL proteins, the underlying pathological mechanisms remain 
obscure.  
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Figure 1. Hypothetical cellular localization of NCL proteins (This scheme was 
originally drawn by Dr. Marco Sardiello’s laboratory) . 
 
1.2 CLN1 Disease 
Infantile neuronal ceroid lipofuscinosis (INCL, infantile Batten disease, or 
infantile CLN1 disease) (MIM#256730) is a rapidly progressing lysosomal 
storage disorder (LSD) caused by defects in the gene coding for palmitoyl 
protein thioesterase-1 (CLN1) (Vesa et al., 1995). This soluble lysosomal 
enzyme is responsible for cleaving long-chain fatty acid residues from 
cysteine residues on a multitude of protein targets. The CLN1 transcript is 
ubiquitously expressed; the nascent PPT1 polypeptide contains 306 amino 
acids, including a 25 amino acid signal sequence which is co-
translationally cleaved (Camp et al., 1994). Mature PPT1 migrates as a 
~37/35 kDa doublet, and is N-glycosylated at N197, N212, N232 in a 
manner essential for the activity, stability, and trafficking of the protein 
(Camp et al., 1994; Bellizzi et al 2000; Das et al. 2001; Lyly  et al. 2007). 
The exact physiological function of PPT1 still remains elusive, but it is 
proposed that PPT1 participates in endocytosis, vesicular trafficking, 
synaptic function and cell death signaling and axonal guidance during 
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development. Lack of PPT1 activity can be used for diagnosis, in this case 
undegraded substrates accumulate in both CNS and systemic tissues. PPT1 
is preferentially localized in cell soma and presynaptic terminals, including 
synaptic vesicles where it may serve a function specific to neuronal cells. 
Invariably mutations in PPT1/CLN1 are associated with granular 
appearance of stored material (granular osmiophilic deposits, GRODs). 
Most mutations are missense and affect residues conserved in diverse 
species. Nonsense mutations or mutations causing frame-shift that result in 
premature truncation of PPT1 are predicted to lead to total loss of 
enzymatic activity. Many of the CLN1 mutations are private but two 
mutations appear with greater frequency: c.364A>T resulting in R122W is 
frequently found in patients of Finnish ancestry, and c.451C>T (R151X) 
has been identified in a more global population of less defined ancestry. 
These two mutations represent about 20% each of the total abnormal CLN1 
alleles. Recently, a structural basis for the effect of CLN1 mutants was 
constructed showing that mutations associated with a total loss of 
enzymatic activity affect the core region of the enzyme, whereas less 
severe mutations are localized at the surface of PPT1 (Ohno et al., 1997). 
The clinical spectrum of CLN1 disease is extremely wide, with age at onset 
varying from infancy to adulthood. The majority of patients are diagnosed 
as infantile-onset NCL, with manifestations in the second half of the first 
year of life in the form of seizures, mental decay, loss of vision and brain 
atrophy. In patients with this NCL form, early development appears normal 
until 6–18 months of age. At on set, there is typically decreased tone and 
decreased social interaction followed by rapidly progressive psychomotor 
regression, myoclonus, seizures, and visual failure. By 2 years of age, there 
is blindness with optic atrophy and macular and retinal changes but no 
pigment aggregation. Progressive brain atrophy is accompanied by a flat 
electroencephalogram. There is also early extinction on the 
electroretinogram. Seizures in infantile NCL may not be as prominent as in 
later-on set forms. Ultimately, spasticity develops and patients become 
vegetative. Fewer cases are seen with onset of symptoms in later childhood 
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(Simonati et al., 2009), adolescence (Perez-Poyato et al., 2011) and even in 
adulthood (Ramadan et al., 2007). Regardless of the age at onset and 
clinical features, the presence of low-absent PPT1 activity and the 
ultrastructural evidence of GRODs are hallmarks of proteolipidic storage in 
all phenotype. The mechanism by which decreased PPT1 activity leads to 
the formation of GRODs remains to be clarified.  
Two mouse models of infantile CLN1 disease were initially developed that 
are completely deficient in PPT1 activity (Gupta et al. 2001; Jalanko et al. 
2005).  More recently, a novel Cln1
R151X
 knock-in model has been 
produced (Miller et al., 2015). These animals recapitulate many features of 
the human disease including progressive neurodegeneration, cortical 
thinning, brain atrophy, autofluorescent accumulation, retinal dysfunction, 
spontaneous seizures, motor deficits and shortened lifespan (Bible et al. 
2004; Griffey et al. 2005; Gupta et al., 2001). In addition, 
immunohistochemical staining for GFAP and CD68 showed reactive 
changes in astrocytes and microglia cell populations, respectively. 
Astrocytosis has been reported in almost all forms of human NCL (Haltia 
et al., 1973). This process mediates how neurons respond to injury, and 
may also influence neuronal function through direct effects upon the 
synaptic environment (Bible et al., 2004). There is growing evidence that 
the activation of astrocytes within the thalamus precedes neuronal cell loss 
(Bible et al., 2004). However, it is still unclear whether astrocytosis 
directly affects neuronal cell loss in the cortex, or if it is a downstream 
consequence of the disease process. The expression of PPT1 in mouse 
brain preparations and cultured neurons parallels with the abundance of 
presynaptic marker protein and indicates a role for PPT1 in synaptogenesis 
(Isosomppi et al., 1999; Ahtiainen et al., 2003), implicated in the recycling 
of synaptic vesicles. The localization of PPT1 in synaptic vesicles, 
however, is a matter of debate (Heinonen et al., 2000; Lehtovirta et al., 
2001; Virmani et al., 2005). The difference in processing and trafficking of 
PPT1 between non-neuronal and neuronal cell types further highlights 
putative distinct functions of PPT1 in neurons (Lyly et al., 2007). Several 
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studies found that changes in the levels of PPT1 expression correlated with 
the activation of caspase-mediated apoptotic pathways in neuroblastoma 
cells and lymphoblasts (Cho et al., 2000; Cho et al., 2000; Zhang et al., 
2001),  which appear to be caused by ER and oxidative stress (Kim et al., 
2006; Kim et al., 2006; Zhang et al., 2006). PPT1 has been repeatedly 
associated with lipid metabolism. Post- mortem brain samples of CLN1 
disease patients revealed changes in phospholipid content. Ceramide levels 
of lipid rafts have been reported to be decreased in CHO cells 
overexpressing PPT1 most likely due to the fact that PPT1 is involved in 
the processing of saposin D, a storage component in CLN1 disease, and 
involved in ceramide catabolism (Goswami et al., 2005; Ahtiainen et al., 
2006). Moreover, early infiltration of CD8 + T-lymphocytes and an 
activation of microglia/macrophage-like cells associated with progressive 
degeneration and loss of retinal ganglion cells was seen in the Ppt1
-/- 
model 
(Groh et al., 2013). 
A recent study have outlined the spatial relationship between lysosomal 
engulfment and damaged mitochondrial reticulum in CLN1 fibroblasts, and 
have demonstrated that the mitochondrial compartment is affected in these 
cells in vitro. Abnormalities in the number, intracellular localization pattern 
and morphology of mitochondria, as well as defects in the mitochondrial 
enzyme activities and adaptive energy metabolism have been observed in 
patient fibroblasts. These results are in agreement with previous studies in 
sheep, Ppt1
-/-
 
mice, and Caenorhabditis elegans (Das et al., 1999; Pezzini et 
al., 2011; Porter et al., 2005; Wei et al., 2011). Additional investigations on 
alterations of the mitochondrial compartment in neuronal cells could reveal 
new insights into the cell pathology of the severe CLN1 encephalopathy of 
childhood. 
Several therapeutic strategies including enzyme replacement, gene therapy, 
stem cell-mediated therapy, and small molecule drugs have resulted in 
minimal to modest improvements in the murine model of PPT1-deficiency. 
However, more recent studies using various combinations of these 
approaches have shown more promising results; in some instances more 
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than doubling the lifespan of PPT1-deficient mice. These combination 
therapies that target different pathogenic mechanisms may offer the hope of 
treating this profoundly neurodegenerative disorder (Hawkins-Salsbury et 
al., 2013).  
 
1.3 CLN5 disease 
The CLN5 form is a variant late infantile subtype of NCL (MIM# 256731) 
originally described in Finland, where a founder p.Tyr392* mutation 
occurs, and later observed on different ethnicities. In Italy, up to 6% of the 
identified NCL cases harbor mutations in CLN5. Onset of the disease is 
usually at 4–7years of age, though rare cases may start in the juvenile 
period or even in adulthood  and manifest with motor clumsiness, language 
delay, progressive visual impairment, and ataxia (Santavuori et al., 1992; 
Santavuori et al., 1993; Holmberg et al., 2000; Mancini et al., 2015). As the 
disease progresses, myoclonus, epileptic seizures, and further mental and 
motor deterioration develop (Santavuori et al., 1991). Affected children 
become blind within 10 years from disease onset, and death usually occurs 
between 10 and 30 years. There is a lag between birth and onset of 
symptoms and in developing blindness that should be weighted as a 
possible therapeutic window if we had the appropriate strategy. 
Pathologically, the CLN5 storage material is made of subunit c of the 
mitochondrial ATP synthase and accumulates in different tissues with 
curvilinear bodies and fingerprint-like structures evidenced at ultrastructure 
(Tyynelä et al., 1997).  
The CLN5 gene encodes a protein (CLN5p) that has a 46 kDa predicted 
molecular mass and no sequence homology to other proteins (Savukoski et 
al., 1998). CLN5p contains a signal peptide (SP) that is cleaved in the 
endoplasmic reticulum (ER) and the mature polypeptide is mainly localized 
in lysosomes, but the full topology of CLN5p is not known. Mature CLN5p 
has mostly been reported to be a soluble protein based on the fact that it is 
secreted, and that it contains mannose-6-phosphate (M6P) residues but its 
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solubility versus membrane-spanning property has been a controversial 
issue (Holmberg et. Al, 2004; Isosomppi et al., 2002; Schmiedt et al., 2010; 
Vesa  et al., 2002). Mutations in CLN5 have been reported to prevent 
trafficking of CLN5p to the level of ER (Lebrun et al., 2009) and Golgi 
(Isosomppi et al., 2002) but also not dramatically affect trafficking to the 
lysosomes (Schmiedt et al., 2010). CLN5p has also been shown to be a 
highly glycosylated soluble lysosomal protein and three of the eight 
potential N-linked glycans at N320, N330 and N401 contain M6P residues 
(Schmiedt et al., 2010; Lebrun et al., 2009; Kollmann et al., 2005; Sleat et 
al., 2006). Recent studies have proposed CLN5p as controlling the itinerary 
of the lysosomal sorting receptors by regulating retromer recruitment at the 
endosome (Mamo et al., 2012) likely because of the possible interactions of 
CLN5p with several other NCL proteins including PPT1/CLN1, 
TPP1/CLN2, CLN3, CLN6 and CLN8 (Isosomppi et al., 2002; Schmiedt  
et al., 2010). Murine Cln5 has a prominent homology to human CLN5; 
Cln5 knockout mouse develops typical symptoms of an NCL disease 
(Holmberg et al., 2004; Kopra et al., 2004). Loss of Cln5 in mice leads to 
defective myelination in vitro and in the developing brain; this is 
accompanied by a defective sphingolipid transport (Schmiedt et al., 2012). 
In double knockout mice (Cln1/5 double-ko) comparative gene expression 
proﬁling in brain has suggested common defective pathways linked to 
neuronal growth cone stabilization (Blom et al, 2013). It has also been 
observed a pronounced accumulation of autofluorescent storage material, 
and an alteration in lipid metabolism (specific increase in plasma 
phospholipid transfer protein activity) with prominent downregulation of α-
synuclein in mouse brains. CLN5-deficient patient fibroblast cells manifest 
increased apoptosis with very low ceramide levels;  addition of CLN8p (the 
product of an additional NCL gene)  or CERS1 (ceramide synthase) (that 
has been recently associated with myoclonus epilepsy and dementia in a 
kindred [Vanni et al., 2014]) brings correction to this phenotype (Schulz et 
al., 2006). The fibroblasts of Cln8-deficient mouse model (Cln8mnd) show 
not only decreased activity of ceramide synthase but also reduced levels of 
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ceramide produced by CERS1, a finding very similar to what is seen in the 
CLN5
 
mutant cells (Haddad et al., 2012) and explaining the ability of 
CLN8p overexpression to complement the CLN5 pathological phenotype.  
In mammals, ceramide represents a central molecule of sphingolipid 
metabolism, implicated in cell signaling, growth, proliferation, 
differentiation, apoptosis, and autophagy. Ceramide is synthesized by a 
family of six synthases (CerS1 to CerS6), each of which utilizes distinct 
acyl chain lengths varying from C14 to C26. In the central nervous system 
(CNS), the most highly expressed ceramide synthase is CerS1, which is 
particularly expressed in neurons of neocortex, hippocampus, and 
cerebellum. CerS1, a transmembrane protein located in the cytosolic leaflet 
of the ER membrane, shows distinctive specificity for (dh)C18-acylCoA 
and represents the main catalyzer of C18 (dh)ceramide synthesis in the 
brain. However, the specific function of C18-ceramides — and of other 
sphingolipid subtypes — is still largely unknown (Levy et al., 2010). 
Alike CLN8p, all mammalian CerS share a distinct domain, the Tram-Lag-
CLN8 (TLC) domain, a region of ∼200 residues also found in other 
proteins. Lipidomic analysis of brain samples from CLN8 patients showed 
reduced levels of ceramide, as well as a decrease in long fatty acyl chain 
containing molecular species within the sphingolipids (Hermansson et al., 
2005). All together these data suggests that CLN8p and CLN5p may act in 
a concerted manner with Cers1 in ceramide synthesis. Intriguingly, some of 
ceramides modulate mitochondrial function and oxidative phosphorylation 
(OxPhos) as they suppress respiratory chain activity, induce ROS 
production and oxidative stress, regulate mitophagy, disrupt the 
mitochondrial membrane potential, and induce mitochondrial outer 
membrane permeabilization (MOMP) and possibly apoptosis. Recently a 
mechanistic link has been established between C18-ceramide produced by 
CerS1 and the induction of mitophagy, suggesting a clue for the 
involvement of Cers1 in neurodegeneration (Sentelle et al., 2012). 
Mitochondrial ceramide directly binds and recruits LC3B-II labeled 
autophagosomes to damaged mitochondria for lysosomal degradation, a 
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condition also termed lethal mitophagy. In fact, generation of C18-
ceramide by CerS1 and ceramide localization to mitochondria were 
required for stress-induced lethal autophagy/mitophagy, which was Drp1-
mitochondrial ﬁssion dependent, placing mitochondrial ceramide in the 
center for selectively inducing lethal mitophagy.  
 
1.4 CLN13-Kufs Disease 
Kufs disease (KD), the most common form of adult NCL, is the least 
frequent and most difficult to diagnose; the symptoms can be vague and 
difficult to sort out among a variety of other disorders (Cotman et al., 
2013). Diagnostic difficulties have delayed discovery of the molecular 
defects underlying adult NCLs. The first genes implicated in KD were 
reported in 2011. KD can present as the Type A form, characterized by 
progressive myoclonus epilepsy or Type B, with movement and behavioral 
abnormalities and dementia (Berkovic et al., 1988). Mutations in CLN6 
represent the major cause of autosomal recessive Type A KD whereas 
variants in DNAJC5 are associated with the autosomal dominant form of 
the disease- Parry disease (Williams et al., 2012). Cathepsin F (CTSF, 
CLN13) mutations have recently been discovered in autosomal recessive 
Type B KD families of French-Canadian, Australian, and Italian origin 
(Smith et al., 2013). The slow progression rate of the disease is also 
observed in cathepsin F-deficient mice showing a late onset accumulation 
of autofluorescent lipofuscin throughout the CNS (Tang et al., 2006). 
CTSF is a widely expressed in human tissues with high levels in the heart, 
brain, skeletal muscle, testis, and ovary; it is a lysosomal cysteine protease 
whose role in vivo is unknown. Cathepsin F is the only cysteine cathepsin 
whose inactivation alone results in a lysosomal storage defect and 
progressive neurological features in mice. CTSF protein consists of 484 
amino acids. After cleavage of a 19 residue signal peptide CTSF is 
modified on oligosaccharides linked to N378 and N440 with M6P-residues 
(Sleat et al., 2006). Of the eleven human cysteine cathepsins, cathepsin F is 
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the only cathepsin that exhibits an extended N-terminal proregion (251 
amino acid), which contains a cystatin-like domain and  it might function 
as an endogenous cysteine protease inhibitor (Santamaria et al., 1999; 
Wang et al., 1998; Wex et al., 1999). Over-expression of N-terminus 
truncated forms of human cathepsin F (Δ-CtsF) in HEK 293T cells have 
recently been associated with features suggestive of aggresome-like 
inclusions, inducing autophagic features (Jerič et al., 2013). In the work in 
question, the truncated forms of human cathepsin F appeared to be co-
localized with aggresome-related proteins such as p62/sqstm1, a 
multifunctional polyubiquitin-binding protein commonly seen in diseases 
with protein aggregation. 
CTSF is synthesized as an inactive preproenzyme that may be targeted to 
the endosomal/lysosomal compartment via the M6P-receptor pathway. The 
physiological function of CTSF is still unclear; but analysis of Ctsf-
deficient mice and in vitro studies indicated that this lysosomal cysteine 
protease is involved in degradation of class II-associated invariant chain 
peptide and MHC class II peptide loading (Shi et al., 2000), lipoprotein 
degradation, potentially linked to the formation of atherosclerotic lesions 
(Tang et al., 2006; Lindstedt et al., 2003; Oörni et al., 2004, angiogenesis 
and tumor-associated inflammation (Smith et al., 2012). Recently, the 
heterologous expression and in vitro studies suggest that cathepsin-F is 
mainly responsible for the lysosomal processing of wild-type lysosomal 
integral membrane protein type-2 (LIMP-2) (Peters et al., 2015). Lack of 
LIMP-2 cleavage may contribute to the pathogenesis of  type-B-Kufs-
disease by impaired lysosomal degradation, leading to a reduced 
autophagic flow and accumulation of engulfed structures, a hallmark of 
many NCLs (Lieberman et al., 2012). 
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Aims 
The overall aim of this research project was to investigate the cellular and 
molecular mechanisms underlying three different forms of NCLs disease 
using patients’ material and cell models. The reasons to investigate CLN1, 
CLN5, and CLN13 is three-fold. First, both CLN1 and CLN5 are relatively 
frequent among the forms in the Italian NCL cohort and the molecular 
pathogenesis is less clear than the other forms such as CLN3 and CLN6. 
Second, the Center where this work was largely undertaken (Simonati’s 
laboratory, “Developmental Neuropathology”; Department of 
Neurological, Psycological, Morfological and Motor Sciences, University 
of Verona) has gained over the past decade a specific expertise in the 
clinical, pathological, and molecular definition of children carrying the 
CLN1 or the CLN5 disease and sufficient biological material was available 
in the laboratory biorepository. Third, the exciting identification of a novel 
disease variant in the Italian group of NCL patients (i.e., CLN13) 
demanded for the use of the tools we had developed in CLN1 and CLN5 to 
further investigate the molecular mechanisms. 
 
Thus, the specific objectives of my PhD work were: 
1. To study the cell pathology caused by Mediterranean CLN1 mutations 
implicated in Infantile neuronal ceroid lipofuscinosis (INCL-CLN1), we 
used human skin fibroblasts of CLN1 patients and derived cultured 
neuroblastoma cells. We tested mitochondrial structure and functions in 
these cells, aiming at the identification of biomarkers of CLN1 disease. 
Human neuroblastoma cells (SH-SY5Y ) are an excellent system in vitro 
and provide an invaluable experimental tool for investigating the molecular 
pathophysiology of NCL disorders in neuronal cell. In this regard, SH-
SY5Y are also valuable because of unlimited proliferation and the ability to 
differentiate into human neuron-like cells. Furthermore, these model 
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systems will offer an opportunity to test in vitro therapeutic and 
pharmacological treatments to modulate mitochondrial functions.  
2.To test the hypothesis that CLN5p (the product mutated in Variant late 
infantile subtype of NCL, vLINCL-CLN5) can be functionally related with 
CerS1 and CLN8p. We studied if such association could also promote 
dysregulated sphingolipid metabolism in disease conditions and if it is 
associated with mitochondrial dysfunction ultimately leading to a 
neurodegeneration. The first objective was to explore the role of the 
CLN5p in terms of functional interactions between CLN5, the lysosomal 
proteins and ceramides, using a cell model system. A second aim was to 
investigate the mitochondrial bioenergetics in patient-derived fibroblasts.  
3. To characterize at the cell level of a novel mutation in CTSF associated 
with Adult NCL- Type B Kufs diseases (CLN13). We investigated the 
putative role of a new N-terminally truncated form of Cathepsin F protein 
in human fibroblasts in terms of protein aggregation and lysosomal storage. 
Use of different cell types permitted for the first type a finer study of 
molecular interaction in CLN5 pathogenesis, the first ever molecular 
investigation in CLN13 disease, and an innovative comparison between 
patients’ derived material and cellular models (developed in Simonati’s 
laboratory) in CLN1 disease. 
 
 
 
 
 15 
 
Results 
2.1 Mediterrean CLN1 mutations are associated with 
mitochondrial dysfunction 
In this study we have used an in vitro system of human neuroblastoma 
cells, SH-SY5Y, reproducing the pathological features observed in 
“Mediterranean” CLN1 mutations. In such cells, we modeled  the missense 
mutation c.665T>C (L222P) which reduces the PPT1 activity and the in-
frame deletion of the second exon (c.125_235del) which predicts loss of 
important residues for protein folding and predicts an unstable gene 
product degraded (Simonati et al., 2009).  
We investigated the mitochondrial and cellular consequences comparing 
results with the corresponding patient’s mutated fibroblasts cell lines. 
To get further insights on the role and functions of the CLN1 protein, we 
studied representative gene mutations that are present in a larger group of 
Italian patients affected by classical and variant CLN1-disease (Santorelli 
et al., 2013). We conducted our experiments in primary cells lines (skin 
fibroblasts) derived from patients and in stably transfected clones over-
expressing the wt and mutated cDNAs. In particular we considered the 
deletion of the second exon (c.125_235del) in which the ORF is maintained 
(Santorelli et al., 1998), but the deletion might cause loss residues needed 
for correct protein folding. Hence, the specific mutation might cause severe 
biochemical defect through protein degradation (Simonati et al., 2009) . 
We also studied a missense mutation, namely, the c.665T>C/L222P, which 
reduces PPT1 enzyme activity. In order to verify the extent of over-
expression of wt and mutated cDNAs, we initially performed 
immunocitochemistry using PPT1 antibody (Fig.2). 
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Figure 2. Stable transfection in SH-SY5Y cells that over-express PPT1 wt and 
mutated. Immunocytochemistry experiments show the results of PPT1 expression 
level in engineered SH-SY5Y cells. PPT-1 is evidenced in green and nuclei are 
counterstained with DAPI.  
 
2.1.1 Analysis of mitochondrial compartment in CLN1 fibroblasts 
In the first part of the study we evaluated the effects of lysosomal storage 
on the mitochondrial compartment in primary mutant CLN1 skin 
fibroblasts, focusing on the structural changes of the mitochondrial 
reticulum. We put attention on two Mediterranean CLN1 mutations, that is, 
c.124+1215_235-102del3.6Kb /p.A43_G145del (variant late-infantile) and  
c.665T>C/p.L222P (juvenile). In primary cells, we observed a 
fragmentation of the mitochondrial network as depicted by porin (VDCA) 
staining. We observed a prevalence of punctuate profile in fibroblasts as 
compared to the regular network of control cell lines which under normal 
condition forms a tubular, regular reticulum, mainly distributed around the 
nuclei, confirming an alteration of the mitochondrial network, as already 
reported (Pezzini et al. 2011). The capacity of patients’ fibroblasts to 
support oxidative phosphorylation was examined by measuring cellular 
ATP production in vitro using a luminometric assay. Fibroblasts were 
cultured with glucose (G) or under conditions that supported only 
glycolytic (glucose with oligomycin, G+O) or mitochondrial ATP 
production (2-deoxy-D-glucose with pyruvate, D+P). Under oxidative 
conditions the ATP levels were significantly reduced in the patients 
compared to control values. (Fig.3) 
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Figure 3. Mitochondrial morpho/functional analysis in fibroblasts. A: 
mitochondrial features of the mitochondrial reticulum (as depicted by Porin 
staining) in CLN1 cells.  B: cells were incubated 2 h in ATP record buffer 
supplemented with 10 mM glucose (Glu), 2.5 mg/mL oligomycin (Oligo), and 5 
mM 2-deoxy-D-glucose plus 5 mM pyruvate (2GD+Pyr).  
P1:  p.L222P; P2: p.V181L/p.A43_G145del. * P value< 0.005. 
 
2.1.2 Differentiation of CLN1 neuroblastoma stable clones 
To assess the functional effect of the two different mutations in CLN1 
(p.A43_G145del and p.L222P), we obtained cells featuring mature neuron-
like structures from stable SH-SY5Y cells line overexpressing the 
mutations. We differentiated clones with stable transfection upon exposure 
to retinoic acid for 6 days (pre-differentiation phase), and we then used a 
enriched neurobasal medium for 3 days (differentiation phase). On parental 
SY5Y cells we observed an increased number of long axonal processes 
(βIII tubulin marker; Fig.4A) and an increase of βIII tubulin expression 
level (Fig. 4B).  Moreover, we demonstrated that stable CLN1 clones were 
able to differentiate after combined treatment with RA and neurobasal 
medium, as demonstrated by the increase expression of some neuronal 
markers (Fig. 4C). In conclusion, the neuronal model generated was able to 
mimic neuronal features and could generate a model to go inside the 
pathological mechanism of the neurodegenerative disease. 
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Figure 4. Differentiation experiment upon exposure to retinoic acid for 6 days (Pre 
differentiation phase), and then to neurobasal medium for 3 days (Differentiation 
phase). A: Immuonofluorescence for βIII tubulin (green) and nuclei are 
counterstained with DAPI. B: Western blotting on parental SH-SY5Y cells using 
βIII tubulin antibody. C: stable SH-SY5Y cells line wt and overexpressing the 
L222P mutation treated with NBM showed an increase in neurite outgrowth 
(green: βIII tubulin; red: SMI31R antibody, specific for heavy chain 
neurofilaments).  
 
2.1.3 Analysis of mitochondrial compartment in CLN1 
neuroblastoma stable clones 
We analyzed the mitochondrial functions in differentiated SHSY5Y wild-
type and stably transfected cells harboring mutations in CLN1 
(p.A43_G145del and p.L222P). The study of mitochondrial network with a 
porin antibody showed mitochondrial fragmentation in the p.L222P clone 
(Fig 5A). The oxidative ATP production was comparable in the different 
cells lines (Fig. 5B) whereas the complex I and complex IV activities, 
evaluated by BN-IGA, showed an increase in the mutant clones when 
compared with SHSY5Y cells. Western blotting using antibodies against 
different subunits of respiratory chain complexes revealed normal steady 
state levels of all subunits (Fig. 6A-B). 
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Figure 5. Mitochondrial morpho/functional analysis in differentiated stable clones 
A: mitochondrial features of the mitochondrial reticulum (as depicted by Porin 
staining) in CLN1 cells.  B: cells were incubated 2 h in ATP record buffer 
supplemented with 10 mM glucose (Glu), 2.5 mg/mL oligomycin (Oligo), and 5 
mM 2-deoxy-D-glucose plus 5 mM pyruvate (2GD+Pyr).  
 
 
Figure 6. Expression of mitochondrial  proteins in differentiated stable clones A: 
cell lysates were separated by SDS-PAGE, and analyzed with specific antibodies 
against different subunits of respiratory chain complexes. Porin and GAPDH were 
used as control for equal loading. B: In gel activity assay of complex I and IV in 
native conditions.  
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2.2 CLN5 is a partner of ceramide synthase enzymes 
We investigated the pathogenetic mechanism underlying the CLN5 disease, 
a rare form of Neuronal Ceroid Lipofuscinoses (NCLs), a variant 
accounting for up to 6% of the Italian NCL population. 
We studied the functional interactions between CLN5, the lysosomal 
proteins and ceramides, using different approaches in a cell model system; 
and analyzed the mitochondrial bioenergetics in patient-derived fibroblasts.  
 
2.2.1 Interactions of CLN5 with other NCL proteins and ceramides 
The possible interactions of CLN5 with other NCL proteins, lysosomal 
hydrolases and ceramides were investigated in appropriate cellular systems. 
We performed bimolecular fluorescence complementation (BiFC) analysis 
in HeLa cells to visualize the direct interactions of proteins in living cells. 
The BiFC assay is based on two non-fluorescent fragments of a fluorescent 
protein which, when fused to two interacting proteins, yield fluorescence 
due to the stable formation of a functional fluorescent protein inside the 
cell. We created construct plasmid expression vectors, using the appropriate 
vectors, by fusing the sequences encoding the selected fluorescent protein 
fragments (YFP - yellow fluorescent protein) with the sequences encoding 
the proteins of interest and expressed them in HeLa cells. Morover we 
tested the interactions between CLN5 constructs Y1-Y2 and a library 
plasmids of lysosomal proteins (Tab.2). The protein interaction was 
visualized and quantified by confocal microscopy (Fig.7A) and Flow 
Cytometric Analysis (FACS) (Fig.7B). We observed a significative 
interaction between CLN5p and CLN8p and of CERS proteins (Cers1, 2, 4, 
5). 
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Figure 7. BiFC analysis. A) Confocal microscopy: pCLN5-YFP1-YFP2, pCLN8-
YFP2, pCERS1-YFP2, pCERS2-YFP2, pCERS4-YFP2, pCERS5-YFP2 and  
pCERS6-YFP2 were transfected into HeLa cells and cultured in normal condition. 
Fluorescence intensities of BiFC (green). B) FACS: percentage of Hela cells 
positives for the interactions.  
 
We also confirmed these interactions using co-immunoprecipitation in 
HeLa cells by transfecting FLAG, MycC and YFP-tagged proteins (Fig.8A-
D). A CLN5-Myc fusion protein expressing in HeLa was used to pull down 
the other proteins. The pull downs were prepared from lysates of HeLa 
cells transiently transfected with different CLN8 and ceramide synthase 
proteins (CERS2,4, 5, and 6) (Fig.8A-D). The bound proteins were 
identified by Western blotting analyses.  
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Figure 8. Co-Immunoprecipitation. Interactions of CLN5 with other NCL 
proteins. The Cln5-cDNA was expressed as Myc fusion protein and used to pull 
down  proteins from HeLa cell lysates. CLN8 (A), CERS1-c-FLAG (B), CERS4-
YFP (C) and CERS5, CERS6-YFP (D). The bound proteins were immunoblotted 
and detected with specific antibodies listed in Methods section. 
 
2.2.2 Intracellular localisation of CLN5 and ceramide synthases 
proteins 
Double immunofluorescence microscopy of HeLa cells transfected with CLN5 
cDNA-YFP showed complete colocalisation of CLN5 protein with the 
endoplasmic reticulum (ER) marker PDI, whereas no colocalisation was detected 
with the marker protein of the late endosomal/lysosomal protein LAMP2 (Fig.9). 
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Figure 9. HeLa cells were transiently transfected with CLN5. Twenty-four hours 
after transfection, cells were fixed and subsequently stained with the GFP 
antibody (green), LAMP2, the ER marker protein PDI (all in red). Merged images 
indicate overlapping localisation (yellow). Nuclei (blue) were visualized by 
staining with DAPI. 
 
Again, double immunofluorescence microscopy of HeLa cells transfected with 
CERs cDNA-YFP (CERS1, CERS2, CERS4, CERS5, CERS6) showed complete 
colocalisation of CLN5 protein with the ER marker PDI, whereas no 
colocalisation was detected with the marker protein of the cis-Golgi (GM130) 
(Fig.10). 
 
Figure 10. HeLa cells were transiently transfected with CERSs. Twenty-four hours 
after transfection, cells were fixed and subsequently stained with the GFP 
antibody (green), the Golgi protein GM130, the ER marker protein PDI  (all in 
red). Merged images indicate overlapping localisation (yellow). Nuclei (blue) 
were visualized by staining with DAPI. 
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2.2.3 Analyses of intracellular trafficking of CLN5 together with the 
CLN8 interacting protein  
To dissect the role of CLN5p interaction with CLN8p in vitro, we 
transiently co-transfected HeLa cells with the CLN5-Myc and CLN8-
FLAG constructs. In the second series of experiment we studied the CLN5-
Myc localization after the silencing with SiRNA CLN8. We observed the 
specific presence of CLN5-Myc in ER compartment in the both conditions 
(Fig.11). The interaction between CLN5p, ER resident proteins and 
CLN8p, occur in the ER, and the presence of CLN5p in that compartment 
is independent of the CLN8p presence. 
 
Figure 11. Consequences in HeLa cells of deficiency of the ER-resident 
trafficking protein CLN8 on the localization of CLN5. HeLa cells were transiently 
transfected alone with the CLN5 (CLN5-Myc) or together with CLN8 FLAG, 
SiRNA CLN8 and SiRNA SC. The cells were fixed with methanol 24 h post 
transfection, stained with the Myc (green), the lysosomal protein (LAMP2) and 
the ER marker PDI (all in red). Merged images indicate overlapping localisation 
(yellow). Nuclei (blue) were visualized by staining with DAPI. 
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To better investigate the role of CLN8 in CLN5 trafficking, we transfected 
MEF cells from wild type and CLN8 deficient (Cln8
-/- 
) mice with CLN5-
Myc. In these murine cells CLN5p we confirmed the results obtained in 
HeLa cells (Fig. 12).   
 
Figure 12. MEF cells were transiently transfected alone with CLN5 (CLN5-Myc) 
or together with CLN8 FLAG. The cells were fixed with PFAl 24 h post 
transfection, stained with the Myc (red), the lysosomal protein (LAMP1) and the 
ER marker PDI  (all in green). Merged images indicate overlapping localisation 
(yellow). Nuclei (blue) were visualized by staining with DAPI. 
 
2.2.4 Lysosomal enzyme activities in CLN5 fibroblasts 
We performed the fluorimetric activities of different lysosomal enzymes, 
causing others forms of lysosomal storage disorders, in wild-type and 
CLN5 patient’s fibroblasts (c.595C>T /p.R99*) primary fibroblast. 
We measured the activities using specifics substrates, we observed a 
significant reduction of TTP1 (CLN2) and β-galactosidase 1 (GLB1) 
(Fig.13A-B).  
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Figure 13. Enzyme activities. Quantification of enzymatic activities expressed as 
arbritary units fluorescent (AUF) in skin fibroblasts from control (C) and patient 
(P). Fluorimetric assay was started by the addition of specifics substrates Ala-Ala-
Phe-NHMec /TPP1, 4-Methylumbelliferyl alpha-D-glucoside (GAA) 3-
Acetylumbelliferyl beta-D-glucopyranoside/ (GBA) and Human beta-
Galactosidase-1 (GLB1). Data are mean ± SD of five different determinations.   
 
2.2.5 Mitochondrial respiration 
To analyze the mitochondrial function in CLN5 disease, we performed 
measurements of OCR and ECAR in adherent ﬁbroblasts (CLN5 mutant-
derived fibroblasts) in real-time micro-oxygraphy with a XF96 
Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA). OCR 
was measured under basal conditions and in response to oligomycin, 
carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone (FCCP), 
Antimycin. The OCR measured under basal conditions (OCR-B), in 
response to oligomycin (OCR-O), and FCCP (OCR-F) did not show 
differences in patient’s cells compared to control’s fibroblasts (Fig. 14A-
B). The same results were obtained when we considered the ratio between 
ECAR/OCR (Fig. 15A). Morover the amount of total mitochondrial ATP in 
the presence of 2-deoxy-Dglucose to block glycolysis in CLN5 patient’s 
cells (c.335G>A/p.R112H and c.595C>T /p.R99* ) was compared to wild-
type fibroblasts. All these results indicated the absence of mitochondrial 
functional alteration in the CLN5 disease (Fig.15B). 
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Figure 14. Panel A shows a representative the graph of oxygen consumption 
(OCR) in different conditions in control and mutant cell line.  As expected, OCR 
in basal conditions (OCR-B) is inhibited when ATP synthesis is blocked by 
oligomycin(OCR-O),whereas is stimulated when oxidation is uncoupled from 
phosphorylation by FCCP (OCR-F). OCR Traces, expressed as pMolesO 2/min. 
CLN5-1: c.335G>A/p.R112H CLN5-2: c.595C>T/p.R99*, CLN5-3: 
c.788T>A /p.V263Q.The histogram in panel B reports the normalization of these 
data to the number of cells/well, expressed as mean values± SD of 12 
replicates/cell line.  
 
 
Figure 15. Panel A shows analysis of OCR/ECAR in basal conditions. CLN5-1: 
c.335G>A/p.R112H CLN5-2: c.595C>T /p.R99*, CLN5-3: c.788 T>A /p.V263Q. 
In panel B we indicated cells incubated 2 hrs in ATP record buffer supplemented 
with 10 mM glucose (Glu), 2.5 mg/mL oligomycin (Oligo), and 5 mM 2-deoxy-
D-glucose plus 5 mM pyruvate (2GD+Pyr).  
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2.3 Impairment of cell autophagy in primary 
CTSF/CLN13 cells 
We identified an Italian family with a vertical transmission of Type B KD 
where we detected a novel homozygous mutation in CTSF. The 42-year-
old proposita presented tonic-clonic seizures since age 23, followed by 
development of cerebellar dysarthria and cognitive decline, finally 
evolving in frank dementia at age 30. Her deceased mother, a maternal aunt 
and a nice also showed a highly similar neurological picture.  Six members 
of this family had a neurological syndrome compatible with KD. The two 
instances of parent-to-child transmission (Fig. 16), suggesting a dominant 
form of dementia such as those observed in Parry disease (Williams et al. 
2012; Velinoy et al., 2012) or in PSEN1-related early-onset Alzheimer 
disease (Schellenberg et al. 2012), constituted initial confounding factors in 
the ascertainment of the causative mutation. Careful clinical assessment of 
the patients, meticulous collection of family history (from local general 
practitioners and through direct interviews with senior family members), 
and recognition of the high degree of inbreeding in the isolated community 
of Fondi, a municipality in central Italy numbering approximately 40,000 
inhabitants, were crucial in disclosing an autosomal recessive pattern of 
inheritance, and therefore in prompting us to consider the possibility of 
mutations in CTSF. 
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Figure 16. Family pedigree.  
 
In subjects III-5, IV-3 and V-1 we detected a new homozygous 
c.213+1G>C mutation in CTSF (Fig. 17A). The mutation was 
heterozygous in eight asymptomatic relatives and excluded in large 
polymorphic databases (including dbSNP and Exome Sequence Variant). 
In cultured skin fibroblasts from the proposita and her maternal aunt, the 
mutation resulted in reduced CTSF/mRNA levels with incorrect splicing 
removing exon 1 and predicting a downstream starting codon with a 
chopped N-terminus of cathepsin F and a probable loss of function 
mechanism (Fig. 17B-C).  
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Figure 17. Molecular Analysis  A. Sequencing results of control (Ctrl) and an 
affected individual (IV-3). Electropherograms of donor splice site region of the 
exon 1 of CTSF flanking the homozygous mutation identified in patient IV-3 at 
position c.213+1G>C (arrow). The wild-type sequence in Ctrl is also shown. B. 
PCR-restriction fragment length polymorphism (PCR-RFLP) for a rapid detection 
of the c.213+1G>C mutation employed the endonuclease DdeI. Using flanking 
oligonucleotide primers, we PCR-amplified a 537-bp fragment. Cleavage with 
DdeI produced 373-, 128-, and 36-bp fragments, both in wild-type subjects and 
control (Ctrl). The presence of the homozygous mutation in subjects III-5 and V-1 
introduced an additional site of cleavage and resulted in 297-, 128-, 76-, and 36-
bp fragments.  The pattern seen in obligate heterozygous individuals (III-3, IV-2) 
shows 373-, 297-, 128-, 76-, and 36-bp fragments. M, 100-bp DNA marker size. C. 
Sequencing results of cDNA from cultured skin fibroblasts from a control (Ctrl) 
and subject IV-3. Electropherograms show part of the CTSF transcript obtained 
using primers located in exon 1 (5’-ctggagggaggactcagg-3’) and exon 4 (5’-
agccatcttcacaggcaagt-3’). Contrary to Ctrl, subject IV-3 lost 264-bp corresponding 
to part of 5’-UTR and exon 1 as well as the canonical start codon. Thus, a new 
transcript is predicted where part of the 5’UTR region is directly joined to exon 2, 
there is a downstream ATG in exon 2, and the transcript is reduced in size.  
Western blotting showed low cathepsin F expression in cultured cells and 
enhanced expression of p62, LC3II and ubiquitin protein, possibly 
indicating disturbed autophagic processes (Fig. 18A-C).  
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Figure 18. Protein Analysis. Representative Western blotting in cell lysates from 
patient IV-3 (P) and a control (C) analyzed for the indicated proteins. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and β-actin were used as 
loading controls. A. Histogram showing a representative expression of human 
cathepsin F where a major band ~70 kDa and a minor band ~30 kDa were found 
to be reduced in IV-3 as compared to a normal control. B. Elevated content of 
LC3B, p62 and Lamp2 proteins is also evident in IV-3 when compared to the 
control. C. Ubiquitin expression was also increased in a soluble fraction of IV-3 
cells.  
 
Immunofluorescence on wild type fibroblasts showed a partial 
colocalization of CTSF and mitochondrial protein (Porin) (Fig. 19A). 
Aggresome formation was observed on patient’s fibroblasts, using a novel  
red ﬂuorescent molecular rotor dye, which is essentially non-ﬂuorescent 
until it binds to the structural features associated with aggregated protein 
cargo. This was similar to observations made when autophagy was induced 
by treatment with the proteasome inhibitor MG 132 (Fig.19B).  
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Figure 19. A. Confocal images (optical sections) showed intracellular cathepsin F 
(CTSF) (green ﬂuorescence) and the mitochondrial marker Porin (red 
ﬂuorescence). Merged images showed overlapping immunoreactivity in yellow. 
B. Aggresome formation as detected using the ProteoStat® aggresome detection 
dye (red ﬂuorescence, **), and Hoechst 33342 nuclear stain (blue ﬂuorescence). 
Cultured skin fibroblasts of patient IV-3 showed aggresome-like features (**) 
similar to control’s cells that had been pre-treated with 5μM of MG-132, a 
proteasome inhibitor.   
 
In Osmiophilic cytoplasmic inclusions suggestive of lipofucsin 
accumulation (aggresome-like structures) were seen ultrastructurally in 
skin biopsies from two patients (Fig. 20). 
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Figure 20. Electron microscopy of patient’s skin biopsy.  
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Discussion 
The Neuronal Ceroid Lipofuscinoses (NCLs) represent a progressive group 
of inherited neurodegenerative diseases. Although the genetic 
underpinnings of most forms of NCL have been identiﬁed, the pathway(s) 
in which neuronal death results in the severe degenerative phenotype 
remain unknown, and there is no available rational basis for treatments. In 
this work we attempted to clarify the cellular and molecular mechanisms 
underlying three different forms of NCLs disease using patients’ material 
and cell models. Our focus was on the identification of distinctive 
pathways that could characterize, at least in part, the diseases associated 
with different genes: CLN1 (causing an Infantile type), CLN5 (determining 
a Late Infantile form) and CLN13-CTSF (responsible for Adult-NCL) Our 
data indicate specific roles for the three affected proteins as follow. 
The CLN1 protein (INCL) seems to be implicated in Oxidative 
metabolism pathways 
We analyzed the mitochondrial compartment in CLN1 deficient skin 
fibroblasts and in an in vitro system of human neuroblastoma cells, SH-
SY5Y, reproducing the pathological features seen in “Mediterranean” 
mutations in CLN1. Mitochondrial morpho/functional analysis showed an 
involvement of the mitochondrial compartment in both cellular systems. 
Our data confirmed previous observations reporting abnormalities in 
number, morphology and intracellular localization pattern of mitochondria 
in pathological primary cell lines (Pezzini et al., 2011). Moreover, a similar 
phenotype was seen in a good cellular model with neuronal-like structure. 
Mitochondrial dysfunctions could be, thus, involved in the pathogenesis of 
NCLs implying that mechanisms such as oxidative stress or apoptosis-
induced via mitochondrial pathway can occur in the brain of CLN1 patients 
and offers further support to the possibility that small nucleophilic and 
lysosomotropic molecules with anti-oxidant properties alone or in 
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combination with  potent antioxidant might have beneficial effects on the 
neurodegenerative process of the disease. 
In perspective, we will examine mitochondrial membrane potential, ROS 
levels in primary skin fibroblast and differentiated neuroblastoma cells in 
normal and stress-induced conditions (using galactose medium as 
metabolic stressor). 
 
The CLN5 protein (LINCL) is a player in abnormal lipid metabolism 
The CLN5 disease is a variant form of late-infantile NCL and the exact 
pathogenetic mechanisms leading gene mutation to cause the disease is still 
unclear. Clinical and neuropathological similarities in NCL disorders may 
result from functional redundancy or co-operation of different NCL 
proteins (Vesa et al., 2002; Sleat et al., 2006) and it is known that the 
addition of CLN8p (the product of an additional NCL gene)  or CERS1 
(ceramide synthase) in CLN5-deficient patient fibroblast cells brings 
correction to the pathological phenotype (El Haddad et al., 2012).  
We demonstrated the molecular interaction between CLN5, other NCL 
proteins, several lysosomal hydrolases and ceramides in an in vitro cellular 
system. In particular we found novel interactions between the CLN5 
protein and four ceramide synthases (CERS1, CERS2, CERSS4, and 
CERS5) that synthesize ceramides, central molecules of sphingolipid 
metabolism in mammalian cells. Alike CLN8, also CLN5 seems to reside 
in the ER compartment but the presence of CLN5p in the ER is 
independent of the CLN8p. Since CLN5 resides in the lumen of 
intracellular organelles, it appears that interaction between CLN5 and the 
transmembrane proteins must be mediated by the lumenal domains of these 
proteins. Our results confirmed that the ER is an important hub station for 
the function and/or trafficking of NCL proteins and that these role do not 
imply a direct connection with mitochondrial inner membrane or 
mitochondrial bioenergetics.  These data foresee a deeper investigation of 
ceramides (levels, pathway of synthesis or both) in CLN5 disease, the 
possible connections with the activation of autophagy or mitophagy 
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pathways, and the ensuing consequences on sphingolipid and phospholipid 
metabolisms. Again these avenues could imply new opportunities to 
hypothesize drug targets. 
 
The CLN13 protein (cathepsin F) has a key role in Autophagy 
mediated processes 
We characterized at the cellular level a novel c.213+1G>C in CTSF 
associated with ANCL- KD Type B (CLN13). The mutation affects correct 
splicing, removing exon 1 and predicting a chopped N-terminus of 
cathepsin F, with a probable loss-of-function mechanism. Overexpression 
of N-terminus truncated forms of human cathepsin F (Δ-CtsF) in HEK 
293T cells has recently been associated with features suggestive of 
aggresome-like inclusions (Jerič et al., 2013) and multifunctional 
polyubiquitinated proteins. We demonstrated in CTSF hypofunctioning 
primary cells from three CLN13 patients ultrastructural features resembling 
aggresome-like structures in skin biopsies. These features were 
biochemically replicated in cultured fibroblasts, where we observed an 
increase of autophagic proteins highly reminiscent of what had been seen 
in HEK 293T cells (Jerič et al., 2013). All these results were suggestive of 
dysregulated autophagy, and points to an as yet unexplored connection 
between autophagy, proteasomal dysfunction and polyUb proteins in 
triggering neuronal cell death in adult-forms of NCL.  
In a larger perspective, our data suggest that the common themes often 
claimed in the broad groups of NCL might be also distinguished at the cell 
levels at an extent that is not possible in murine models of the disease since 
those experimental system lack of the specificity offered by the human 
genetic background or point to mechanisms that are only partially applied 
in human NCL disease. Future approaches adopting also the 3-ome 
strategies could also impinge on these differences while searching novel 
therapeutic targets.  
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Conclusions  
The NCL share clinical manifestations, biochemistry, and pathology, hence 
their classiﬁcation together. NCL protein deﬁciencies result in similar cell 
biologic phenotypes including dysregulation of apoptosis and autophagy, 
prolonged inflammation, disturbed endoplasmic reticulum–cytosol calcium 
balance, impaired oxidative metabolism, and abnormal lipid trafficking. 
There are evidences that NCL proteins are essential components of a 
common pathway and that they may interact at multiple locations (Persaud-
Sawin et al., 2007). It is possible to speculate on the possibility that a 
disruption in a common biological process leads to an NCL-disease. Yet, 
the possibility that individualized or specific mechanisms are more 
important in specific subtypes could offer more personalized approaches to 
cure. 
To sum up, in this study we dissected at the cell level some of the 
specificities in three different forms of NCL pathology that are mostly 
relevant to Italian patients and our results pinpoint different steps in NCL 
disease and the involvement of specific cellular processes in the 
pathophysiological function of NCL proteins. The use of cell or model 
systems derived from affected individuals could also overcome some of the 
emerging conundrum of genetically-modified animal models where the 
pathogenic steps seem of discussed value in fully replicating the human 
pathology (Simonati et al, 2014). In perspective, all these steps and their 
specificities should be further explored to define steps more relevant as 
those might represent specific targets for developing more rationale 
therapeutic options.  
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Materials and Methods 
4.1 Cell cultures and differentiation media  
Human fibroblasts have been collected according to standard procedures 
from diagnostic skin biopsies.  
Primary culture of human fibroblasts from:  
1. Two patients harboring “Mediterranean” CLN1 mutations. Patient 1 
(Pt.1) was found to carry the homozygous c.665T>C mutation [p.L222P] 
whereas patient 2 (Pt.2) was compound heterozygous for the 
c.541G>T/c.124+1215_235-102del3.6Kb [p.V181L/p.A43_G145del]. 
2. CLN5 patients carrying different mutations in CLN5: 
c.788T>A/p.V263Q, c.335G>A/p.R112H and c.595C>T /p.R99*. 
Moreover we used MEF (mouse embryonic fibroblasts) cells from wild 
type and CLN8 deficient (Cln8
-/-
) mouse, HeLa cells from cervical tumor 
cells. The mouse model was generated in Dr Sardiello’s laboratory at the 
Department of Human Genetics, Baylor College of Medicine, Houston 
(Texas). 
3. CLN13 Patients’ derived fibroblasts were obtained from punch 
biopsies of the affected individuals described in Di Fabio et al, 2014. A 
brief summary of clinical data of this novel form of adult-onset NCL is 
presented in Appendix. 
All cell lines were grown at 37 °C with 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM), containing 10% fetal bovine serum (FBS), 4.5 
g/L glucose and 1% antibiotics/antimycotics. 
Neuroblastoma cell line SH SY5Y was cultured in DMEM/F12 1:1 with 
10% FBS, 15 mM Hepes, L-glutamine, penicillin/streptomycin and 
amphotericin B (all purchased from Euroclone). Stable transfected clones 
were cultured in presence of 600 µg/ml G-418 (Geneticin, Euroclone). At 
70-80% of confluence, cells were trypsinized and seeded at lower 
concentration (about one tenth). For neuronal differentiation, we set a 9 
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days long paradigm (hereafter referred as RA-NBM treatment) consisting 
in 2 phases: a 6 days pre-differentiation step in basal medium with  5% 
FBS and 10 μM all trans Retinoic Acid (RA, Sigma Aldrich) followed by a 
3 days differentiation step in neurobasal medium (GIBCO, Life 
Technologies) enriched with 50 ng/ml recombinant human BDNF 
(rhBDNF, Peprotech), 2 mM dibutyril-cyclic AMP (dbcAMP, Sigma 
Aldrich), B27 Neuromix (Euroclone), 20 mM KCl, 1% L-glutamine 
(NBM). Briefly, 5000 cells per cm2 were seeded on flasks or alternatively 
on coverslips previously coated with ECMax gel (Sigma Aldrich), allowed 
to adhere for 24-48 hours and then exposed to basal or conditional media. 
Media were routinely changed every 2-3 days and the morphological 
features of the cultures were checked by phase contrast microscopy 
(Palomo et al., 2011).  
 
4.2 Transfection 
Transient transfection of wt and mutated cDNAs was performed in SH 
SY5Y cells. Stable transfected clones overexpressing the wt and different 
mutations of CLN1 cDNA are obtained after antibiotic selection with 
geneticin (G418, Gibco, LT) at 600 g/ml.  
Molecular analysis and trasfection of neuroblastoma cells were performed 
in collaboration with the Unit of Molecular Medicine of Children Hospital 
“Bambino Gesù”, Roma. 
The protocols for the Lipofectamine LTX kit (Invitrogen) were followed 
for HeLa cells and the protocol of the Metafectene kit (Biontex 
Laboratories) was used for MEF cells. 
4.3 Molecular analysis 
The preparation of CLN1 cDNAs (NM_000310) encoding wild-type (wt) 
and mutant (either c.125_235del or c.665T>C) inserted in pcDNA3 
expression vector (Invitrogen, LT) were performed by standard PCR 
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methods. We confirmed the sequence both wt and mutated CLN1 plasmids, 
by direct sequencing, using the BigDye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems, Foster City, CA) on an ABI3130xl automatic 
DNA Analyzer. 
The CTSF/CLN13 gene was analyzed in peripheral blood DNA by PCR 
amplification and direct sequencing using BigDye 3.1 chemistry (Applied 
Biosystems, Foster City, CA, USA) and intronic oligonucleotide primers 
flanking the coding exons (sequences are available upon request). Gene 
deletions/duplications were excluded by the multiplex amplicon 
quantification (MAQ) technique. Nomenclature of mutations followed the 
guidelines of the Human Genome Variation Society 
(http://www.hgvs.org/mutnomen) and refers to the cDNA sequence 
(Genbank reference sequence version NM_003793.3) with the A of the 
translation initiation codon as +1.  
We searched for all possible new single nucleotide variants (SNVs) both in 
a large set of in-house control chromosomes and in the dbSNP and Exome 
Variant databases (respectively http://www.ncbi.nlm.nih.gov/projects/SNP/ 
and http://evs.gs.washington.edu/EVS). New SNVs were also 
systematically evaluated in silico to predict their effects on protein function 
by means of Mutation Taster (http://www.mutationtaster.org/),  Condel 
(http://bg.upf.edu/condel/), Polyphen analysis 
(http://genetics.bwh.harvard.edu/pph2/index.shtml) and ESEfinder 
(rulai.cshl.edu/new_alt_exon_db2/HTML/score.html and www.fruitfly.org 
/seq_tools/splice.html).  The c.213+1G>C mutation was ruled out in 
control alleles and segregation was checked for in the family by ad hoc 
mutation-specific PCR-restriction fragment length polymorphism analysis.  
Total RNA was purified from cultured skin fibroblasts obtained from 
patients and age-matched normal controls using TriReagent (Sigma-
Aldrich, Milan, Italy) and was reversely transcribed using the 1st Strand 
cDNA Synthesis Kit (Roche, Hamburg, Germany) according to the 
manufacturer's random primer protocol. The consequences of the 
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c.213+1G>C mutation on splicing were examined by RT-PCR using 
primers located in the 5’UTR and in exon 4. 
Mutations in knon NCL genes had been excluded in patient IV-3 prior to 
testing CTSF. 
 
4.4 Immunofuorescence assay 
For immunofluorescence analysis, paraformaldehyde-fixed coverslip-
grown fibroblasts in antigen retrieval buffer [0.1MTris, 5% (w/v) urea, pH 
9.5] were heated at 95°C for 10 min, followed by 15 min treatment with 
0.1% Triton X-100 at room temperature. Slides were then incubated 
overnight at 4°C with mouse monoclonal anti-porin (Mitosciences, Eugene, 
OR), mitochondrial marker, and a rabbit anti-human cathepsin F polyclonal 
antibody (Santa Cruz) and in the presence of 10% FBS.  
Neuroblastoma cells were fixed in 4% paraformaldehyde (PFA) for 20 
minutes at RT. Cells were incubated in blocking buffer (10% normal goat 
serum, 0.3% Triton in PBS,) for 1h and then incubated over-night with the 
following primary antibodies: antibodies: anti-PPT-1 (1:50, Sigma),  anti-
βIII tubulin ( 1:100, Rabbit- Cell Signal Technology), anti-SMI-31 (1:100, 
Covance), anti-NF160 KDa (clone BF10) mouse monoclonal (1:100, 
Boehringer Mannheim). For fluorescence inspection, we used anti-mouse 
IgG (AbCam, Cambridge, UK) secondary antibodies conjugated with 
Alexa Fluor 488 and 555 (Molecular Probes) as well as 4',6-diamidino-2-
phenylindole (DAPI) for nuclear staining. Images were acquired by an 
AxioCam equipment using AxioVision 4.3 software (Carl Zeiss). 
HeLa cells were fixed with 100% ice methanol for 10 min, MEF cells were 
fixed with 4% PFA for 20 min at room temperature (RT). Blocking in 0.1% 
saponin, 10% FBS in PBS 1h RT. Slides were then incubated overnight at 
4°C with primary antibody (1:200) in blocking solution. Primary antibodies 
were the following anti-Lamp2 (Mouse, Santa Cruz), anti-Lamp1 (Rat, 
Santa Cruz), anti-GFP (Chicken, Abcam), anti-FLAG (Rabbit, Sigma), 
anti-Myc (mouse and Rabbit, Sigma), anti-PDI (Mouse, BD bioscience), 
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anti-GM 130 (Rabbit, Abcam). For fluorescence visualization, we used 
secondary antibodies conjugated with Alexa Fluor 555 and  488 goat-anti 
mouse IgG,  goat-anti rabbit IgG, goat-anti Chicken IgG and goat-anti Rat 
IgG (Molecular Probes), as well as 4',6-diamidino-2-phenylindole (DAPI) 
for nuclear staining. Images were acquired by confocal microscope (Zeiss 
LSM 710).  
 
4.5 Aggresome detection 
Cellular aggresomes were detected using the ProteoStat® Aggresome 
Detection kit according to the manufacturer's instructions (Enzo 
LifeSciences, Lausanne, Switzerland). Cultured cells were grown on 
coverslips and incubated for 12 h with MG-132, a cell-permeable 
proteasome inhibitor (5μM), which was used as a positive control. The 
cells were then washed with PBS, ﬁxed in 4% paraformaldehyde for 30 
min at room temperature, and permeabilized in permeabilizing solution 
(0.5% Triton X-100, 3 mM EDTA, pH 8.0 in 1× assay buffer) with gentle 
shaking on ice for 30 min. After this step, the cells were washed again in 
PBS and stained using the ProteoStat® Aggresome Detection Reagent and 
Hoechst 33342 nuclear stain for 30 min at room temperature protected 
from the light. The aggresomes were visualized using a Zeiss AX10 
inverted fluorescence microscope equipped with an AxioCam MRc5 
camera. The images were processed using AxioVision rel 4.8 acquisition 
software (Zeiss). 
 
4.6 SDS-PAGE and Western Blotting 
For Western blotting (WB) analysis, cultured skin fibroblasts,   
neuroblastoma stable clones and  trasfected HeLa cells,  were collected at 
conﬂuence, washed twice with PBS and then homogenized in RIPA buffer 
(150 mM NaCl, 50 mM Tris–HCl, 6 mM EDTA, 1% NP-40, 0.1% SDS, 
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0.5% deoxycolic acid, pH 8.0) containing inhibitors of proteases (Roche 
Diagnostics GmbH, Mannheim, Germany). The cells were disrupted by 1 h 
incubation on ice and centrifuged for 10 min at 16,000 ×g  at  4°C. The 
supernatant (soluble fraction) was collected and either used immediately or 
stored at −20 °C for later use. The pellets (insoluble fraction) were 
solubilized in 50μl of 1% (v/v) SDS in PBS for 10 min at room 
temperature; then, following addition of 50μl RIPA buffer, they were 
sonicated for 10 s. A 12% denaturing gel was loaded with 30-50 μg 
proteins. Proteins were then electron-transferred to nylon membranes 
(purchased from Bio-Rad Laboratories, Hercules, CA); the membranes 
were blocked with TBS/0.1% Tween20 (TTBS) containing 10% non-fat 
dry milk and then subjected to immunoblotting analysis. Primary 
antibodies were incubated overnight at 4°C in TTBS with 5% non-fat dry 
milk, and those not bound specifically were removed by washing in TTBS. 
Peroxidase-conjugated anti-mouse and anti-rabbit were used as secondary 
antibody (Jackson ImmunoResearch, laboratories Inc.) were added for 1 
hour at room temperature in the same buffer as used for the primary 
antibodies (5% non-fat dry milk in TTBS). Reactive bands were detected 
using Immobilon Western Chemiluminescent HRP Substrate (Millipore 
Corporation, Billerica, MA), according to the manufacturer’s instructions.  
Quantitative blot analysis was performed using ImageJ software 
(http://rsbweb.nih.gov/ij/). 
The primary antibodies used for WB analysis were: 
1. Mitochondrial OXPHOS complexes: NDUFS3(30 kDa), SDHA (70 
kDa), Core protein 2, COXII, CVα. VDAC/Porin, as a control for 
protein loading; (1:1000, Mitosciences,  Eugene, OR, USA). Anti-
GAPDH (1:10000, Abcam) and anti-βIII tubulin (1:1000, Cell Signal 
Technology). 
2. Anti-FLAG mouse (1:5000, Sigma), anti-GFP mouse (1:1000, Roche 
Applied Science) and anti-Myc rabbit (1:1000, Sigma).  
3. Anti-cathepsin F (1:500; Santa Cruz Biotechnology, Heidelberg, 
Germany), monoclonal anti-Lamp2 (1:8000; H4B4 clone Abcam, 
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Cambridge, UK), polyclonal anti-LC3II (1:2000; Cell Signalling 
Technology, Santa Clara, California), anti-ubiquitin (1:500, Dako, 
Beverley, MA), and monoclonal anti- p62/sqstm1 (1:2000; BD 
Biosciences, Oxford, UK). Monoclonal mouse anti-β-actin (1:50.000; 
Sigma-Aldrich) and rabbit polyclonal anti-GAPDH (1:10,000; Sigma-
Aldrich) were employed as loading controls. 
 
4.7 Mitochondrial Protein Preparation 
Mitochondrial pellets were isolated from cell cultures as described 
elsewhere (Calvaruso et al.,2008). Briefly, fibroblasts were cultured until 
cells were70% confluent. Cells were harvested with trypsin, washed twice 
with phosphate-buffered saline (PBS), and re-suspended in 100 μl PBS 
plus 100 ml of digitonin solution (4 mg/ml). The cell solution was kept on 
ice for 10 min to dissolve the membranes. One milliliter of cold PBS was 
added to the cells, which were spun for 10 min at 10 000 r.p.m. at 4C. The 
supernatant was removed, the pellet washed one more time in 1 ml cold 
PBS, and the protein concentration was determined using the BCA protein 
assay kit (Pierce). For the preparation of native mitochondrial complexes, 
pellets were solubilized in 100μl buffer containing 1.5M aminocaproic 
acid, 50 mM Bis – Tris, pH 7.0. Next, 1% (w/v)n-dodecyl b-D-maltoside 
was added and solubilized samples were incubated on ice for 15min and 
centrifuged for 30 min at 13,000 rpm at 4° C, and the supernatant was 
combined with 10μl of sample buffer (750 mM aminocaproic acid, 50 
mMBis – Tris, 0.5 mM EDTA, 5% Serva Blue G-250) prior to loading.  
antibodies. 
 
4.8 Blue Native Analysis  
Blue native 3 – 13% gradient gels were loaded with 60μg of mitochondrial 
protein using 50 mM Bis – Tris as an anode buffer and 15 mM Bis – 
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Tris/50 mM tricine containing 0.02% Serva Blue G-250 as a cathode 
buffer. After electrophoresis, proteins were transferred to a PVDF 
membrane at 35 V, overnight, and probed with specific antibodies (proteins 
were subjected to Western blotting. Duplicate gels were further used for in-
gel activity (IGA) assays. 
 
4.9 IGA assay 
In-gel activity assays entail the incubation of the gels in complex speciﬁc-
solutions that contain substrates and color reagents which stain upon the 
acceptance of electrons or phosphate. Because the OXPHOS complexes are 
native they still have enzymatic activity. Combination of the appearing 
stained bands and their molecular weight allow good and quantitative 
identiﬁcation of the individual complexes. Gels are incubated at room 
temperature with the following solutions: Complex I: 5 mM Tris–HCl, pH 
7.4, 0.1 mg/ml NADH, and 2.5 mg/ml NTB (NitroTetrazolium Blue, 
Sigma).Complex IV: 50 mM sodium phosphate buffer, pH 7.2, 0.5 mg/ml 
3.3’ -diamidobenzidine tetrahydrochloride (DAB, Sigma–Aldrich) 0.05 
mM cytochrome c (horse heart <95% purity, Sigma). 
 
4.10 Total and mitochondrial ATP assay 
ATP levels were measured using the Luminescence ATP Detection Assay 
System (ATPlite one step, PerkinElmer Life Sciences). Briefly, 1x10
4
 and 
3x10
4
, respectively for cultured fibroblasts and SH-SY5Y cells, were used 
and they were seeded in a 96-well plate (1 x 10
4
 cells/well) and incubated 
in 10% FBS/DMEM medium for 48 h. After discarding the medium, cells 
were washed with ATP record buffer (156mM NaCl, 3mM KCl, 2 mM 
MgSO4, 1.25mM KH2PO4, 2 mM CaCl2, 20mM HEPES, pH 7.35) and  
incubated for 2 h in buffer with either 10 mM glucose, 10 mM glucose plus 
2.5 μg/ml oligomycin (glycolytic ATP generation), or 5 mM 2-deoxy-
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Dglucose plus 5 mM pyruvate (oxidative ATP production) (Nogueira et al., 
2013).  
Then cells were incubated with the luciferin/luciferase reagent and ATP 
production in samples was measured using an Orion L Microplate 
Luminometer (Berthold Detection Systems GmbH). 
 
4.11 Transmission electron microscopy 
Specimens from skin biopsies were fixed in 2.5% glutaraldehyde in 100 
mM phosphate buffer for 3 hours at 4°C. After washing in buffer, samples 
were the post-fixed in 1% osmium tetraoxide for 2 hours at 4 °C, 
dehydrated by increasing concentrations of acetone and subsequently 
embedded in Spurr resin. Ultra-thin slices were cut by microtome, stained 
in uranyl acetate and lead citrate and finally observed under the EM 109 
electron microscope (Carl Zeiss, Munich Germany). 
 
4.12 Cloning  
We created construct plasmid expression vectors, using the appropriate 
vectors, by fusing the sequences encoding the selected protein fragments 
(YFP - yellow fluorescent protein, Myc and FLAG) with the sequences 
encoding the proteins of interest. 
We generated linearized expression vectors (p3XFLAG-CMVTM-13-
Sigma, pcDNA 3./cmyc- His A-Invitrogen, MCFD2-YFPC and YFPN-
ERGIC 53) using restriction endonucleases (Not1, BamH1, HindIII, EcoRI, 
ClaI and XhoI; New England Biolabs); then we gel purified the linearized 
vector using Gel Ectraction kit (Qiagen).  For the directional cloning of one 
fragment of DNA into the vectors we used the In-Fusion HD Cloning Kit 
(Clontech® Laboratories, Inc.), this method permits to fuse DNA 
fragments (e.g. PCR-generated sequences and linearized vectors), 
efficiently and precisely by recognizing a 15 base pairs (bp) overlap at their 
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ends. This 15-bp overlap can be engineered by designing primers for 
amplification of the desired sequences (Tab. 2). 
 
 
 
 
 
 48 
 
Table 2. Primers used for the designing constructs YFPN-YFPC of the CLN5, 
CERS1, CERS2, CERS4, CERS5, CERS6 genes. 
 
We amplified the genes of interest using CloneAmp HiFi PCR Premix: 
(conditions were 35 cycles of 98°C 10 sec, 63°C 10sec, 72°C 1 min). The 
purified PCR fragment was fused with the linearized vector in the in-
Fusion cloning reaction and incubated for 1h at 50°C. Afterward we 
cotransformed Stellar competent cells using standard method of heat shock 
with the plasmids containing the fusions and plated them on ampicillin 
(AmpR) selective LB plates. We incubated all plates overnight at 37°C. 
The following day we picked individual isolated colonies from each 
experimental plate. To determine the presence of insert, we isolated 
plasmid DNA using a mini prep kit (Pure Link TM Quick Plasmid 
Miniprep Kit, Invitrogen), analyzed the DNA by restriction digestion or 
colony PCR screening (SapphireAMP Fast PCR master mix, Clontech® 
Laboratories, Inc.), and confirmed the presence of insert by sequencing 
(Fig.21) 
 
Figure 21. Protein fusion vectors. Plasmid maps of vectors encoding the protein 
fusions CLN5-NYFP  (inserted in the plasmid  ERIGC53) and CLN5-CYFP 
(inserted inthe plasmid MCFD2) 
Cells were transfected with different cDNA-vector constructs.  
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4.13 Bimolecular fluorescence complementation 
(BiFC) analyses 
The BiFC assay is based on two non-fluorescent fragments of a fluorescent 
protein which, when fused to two interacting proteins, yield fluorescence 
due to the stable formation of a functional fluorescent protein inside the 
cell. The analysis was performed as previously described (Kerpolla et al., 
2008) (Fig.22). 
 
 
Figure 22. Schematic representation of the principle of the BiFC assay. Two 
nonﬂuorescent fragments (YN and YC) of the yellow ﬂuorescent protein (YFP) 
are fused to putative interaction partners (A and B). The association of the 
interaction partners allows formation of a bimolecular ﬂuorescent complex.  
 
Protein fusion vectors: YFP N-terminal fragment (Y1), YFP C-terminal 
fragment (Y2), (Tab.2). The library of lysosomal proteins constructs was 
generated in the laboratory of Dr Sardiello, Department of Human 
Genetics, Baylor College of Medicine, Houston (Texas) (Tab.3). 
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Table 3. Library of lysosomal proteins  for BiFC constructs (YN-YC)  
ACP5 acid Phosphatase 5 Tartrate Resistant GNS glucosamine (N-acetyl)-6-sulfatase 
AGA aspartylglucosaminidase GUSB beta glucuronidase 
ARSA arylsulfatase A HEXB hexosaminidase B 
ARSB arylsulfatase B HPSE Heparanase 
ARSG arylsulfatase G HYAL1 hyaluronoglucosaminidase 1 
ARSK arylsulfatase K IDS iduronate 2-sulfatase 
ASAH1 N-acylsphingosine amidohydrolase MAN2B1 mannosidase alpha class 1B 
CTBS Chitobiase, Di-N-Acetyl MAN2B2 mannosidase, alpha, class 2B 
CTSA cathepsin A MANBA mannosidase beta A 
CTSB cathepsin B MPO Myeloperoxidase 
CTSC cathepsin C NAAA N-acylethanolamine acid amidase 
CTSD cathepsin D NAGA N-acetylgalactosaminidase, alpha- 
CTSF cathepsin F NAGLU N-acetylglucosaminidase alpha 
CTSH cathepsin H NEU1 sialidase 1 
CTSK cathepsin K NPC2  Niemann-Pick disease, type C2 
CTSO cathepsin O PCYOX1 prenylcysteine oxidase 1 
CTSS cathepsin S PLA2G15 phospholipase A2, group XV 
CTSZ cathepsin Z PLBD2 phospholipase B domain containing 2 
DNAS2 deoxyribonuclease II PPT2 palmitoyl-protein thioesterase 
ERGIC53 ER-Golgi intermediate compartment  PSAP Prosaposin 
FUCA1  fucosidase, alpha-L- 1 RNASET2 ribonuclease T2 
GAA glucosidase alpha acid SCARB2 lysosomal membrane sialoglycoprotein 
GALC galactosylceramidase SCPEP1 serine carboxypeptidase 1 
GALNS galactosamine (N-acetyl)-6-sulfate SGSH  N-sulfoglucosamine sulfohydrolase 
GBA Glucosidase beta acid SIAE sialic acid acetylesterase 
GGH gamma-glutamyl hydrolase  SMPD1 sphingomyelin phosphodiesterase 1 
GLA gamma-carboxyglutamic acid TPP1 tripeptidyl peptidase I 
GLB1 Galactosidase beta 1 PPT1 palmitoyl-protein thioesterase 1 
GM2A GM2 ganglioside activator CLN8 ceroid lipofuscinosis, neuronal, 8 
    
 
For microscopy: 1x10
4
 
HeLa cells/well in 8-chamber slides were 
transfected with 500 ng of total DNA. Cells were visualized on confocal 
microscope (Zeiss LSM 710) 24h after the transfection in PBS buffer. The 
microscope equipped with a camera (or similar equipment) at a 
magnification of 20X. To visualize the YFP, used as a reporter protein, a 
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filter for GFP excitation (450–495 nm) and a GFP emission filter (515–560 
nm) were required.  
 
For flow cytometric we plated 8x10
4
 Hela cells/well in 24-well chamber 
with 600 ng of total DNA. To quantify the efficiency of fluorescence 
complementation, it was necessary to include an internal control in the 
experiment to normalize for differences in transfection efficiency and the 
level of protein expression. For this purpose, cells were cotransfected with 
plasmids encoding the two fusion proteins (e.g., fused to YFPN and 
YFPC), together with a plasmid encoding a full-length fluorescent protein 
with distinct spectral characteristics (peseudo-colored red, CFP). Cells 
transfected were analyzed after 48h, resuspended cells in 1%FBS/PBS. 
Flow cytometry was performed using a BD LSRFortessa cell analyzer (BD 
Biosciences). The fluorescence intensities produced by both BiFC (YN-
YC) and the internal control (CFP, cells transfected) were measured in 
individual cells. The ratio of YN-YC to CFP emission was calculated after 
subtraction of background signal (negative control-pCDNA). The ratio of 
YN-YC to CFP fluorescence is a measure of the efficiency of BiFC. The 
ratios for different structurally related fusion proteins can reflect the 
relative efficiencies of complex formation (the positive interaction) in 
living cells (Fig.23). 
 
 
 52 
 
 
Figure 23. Flow cytometry: Gating for ﬂow cytometry analysis of fluorescent 
protein expressing in HeLa cells. A) CFP protein (Red signal) B) pcDNA 
(negative control-no signal) C) YFP protein (Green signal) D) CFP+YFP (Red-
Green) cells positive for the interaction. 
 
4.14 Co-immunoprecipitation 
HeLa cells, 60 mm
2
 (1.2x10
6
 cells) dishes were co-transfected with a total 
of 7.5 mg of DNA that included: plasmid encoding FLAG- CERS1 and 
CLN8 proteins, plasmid encoding a CLN5 Myc and YFP- CERS proteins 
(CERS2, CERS4, CERS5 and CERS6). A variable amount of DNA was 
transfected for particular constructs to ensure similar levels of expression. 
About 48 h after transfection, cells were lysed with 1.0% Nonidet P-40 
buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 10% glycerol, 1 mM DTT, 
EDTA-free protease inhibitor pellets (Roche Applied Science). 200 g of 
total protein from transfected Hela cells were used for individual coIP 
experiments. Lysates were incubated with primary antibody for 30 min and 
precipitated for 4 h with 10 l of protein G agarose (Roche Applied 
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Science) at 4 °C. FLAG proteins were immunoprecipitated and 
immunoblotted with a mouse monoclonal anti-FLAG antibody (1:5000, 
Sigma). GFP fusion proteins were precipitated and immunoblotted with a 
mouse monoclonal anti-GFP antibody (1:1000, Roche Applied Science). 
Myc protein was immunoprecipitated and immunoblotted with a rabbit 
polyclonal anti-Myc antibody (1:1000, Sigma). Samples were run on SDS-
PAGE, 4 –12% Bis-Tris gel (Invitrogen) immunoblotted with indicated 
antibodies and visualized with HRP-conjugated anti-mouse or anti-rabbit 
secondary antibodies, detected using ECL chemiluninescence for 
immunodetection. 
 
4.15 Enzyme activity assays 
Fibroblasts were seeded in a 96-well plate (1 x 10
4
 cells/well) and 
incubated in 10% FBS/DMEM medium for 24 h. After discarding the 
medium, cells were incubated in 0.2 M acetate buffer (pH 4.5) containing 
0.1% Triton X-100 (v/v). Fluorimetric assay was started by the addition of 
specifics substrates Ala-Ala-Phe-NHMec (Sigma)/TPP1 (Vines et al., 
1999), 4-Methylumbelliferyl alpha-D-glucoside (Sigma)/Glucosidase alpha 
acid (GAA) (Wen Yang et al., 1998), 3-Acetylumbelliferyl beta-D-
glucopyranoside (Sigma)/ Glucosidase beta acid (GBA) (Song et al., 2013) 
and Human beta-Galactosidase-1 (R&D system)/Galactosidase beta 1 
(GLB1) (Brunetti-Pierri et al., 2009). Reactions were incubated at 37°C for 
2-6 hrs. Fluorescence was measured (excitation 360 nm, emission 460 nm) 
with a Gen5 microplate reader (BioTek Instruments). 
 
4.16 OCR and ECAR measurements 
Oxygen consumption rate (OCR) and extra-cellular acidification rate 
(ECAR) were measured in adherent fibroblasts with a XF96 Extracellular 
Flux Analyzer (Seahorse Bioscience, Billerica, MA, USA). Each control 
and mutant fibroblast cell lines were plated in XF 96-well cell culture 
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microplates at a density of 2.5–7.5 × 103 cells/well in in 200 μL of DMEM 
and incubated for 24 h at 37 °C in 5% CO2 atmosphere. After replacing the 
growth medium with 175 μL of XF media (non-buffered DMEM medium, 
containing 5 mM glucose, 0.5 mM L-glutamine, ph 7.62), pre-warmed at 
37°C cells were preincubated for 30 min. before starting the assay 
procedure. After baseline measurements of OCR (OCR-B) and ECAR, 
OCR was measured after sequentially adding to each well oligomycin and 
carbonyl cyanide 4-(trifluoromethoxy) phenylhy-drazone (FCCP), to reach 
working concentrations of 1μg/ml and 0.4 μM, respectively. We evaluated 
the fraction of non-mitochondrial oxygen consumption, by measuring OCR 
after complete inhibition of the mitochondrial respiratory chain with 
antimycin 1 μM (all chemical were from Sigma Aldrich) (Invernizzi et al. 
2012).  
 
Statistical analysis and data processing 
The mean+SEM values of at least three independent experiments are 
represented in the ﬁgures. Statistical comparison of the data sets was 
performed using Student’s t-test. The differences are presented with their 
corresponding statistical signiﬁcance or P-value. 
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Appendix 
Patients CTSF 
The proposita (IV-3), a 42 years old when first seen by us, is a woman 
who, at age 23 years, presented clusters of tonic-clonic seizures, fully 
controlled by a combination of sodium valproate (1250 mg/day) and 
carbamazepine (1200 mg/day). Her medical history was only remarkable 
for mild head traumas that occurred at age 28 years. From the age of 30, 
she showed a progressive cognitive decline. She rapidly became aphasic 
and displayed suprabulbar signs. Her relatives reported sporadic lower limb 
myoclonic jerks. In recent years neurological examination had revealed 
transient facial dyskinesias, which had first appeared several years after the 
onset of the cognitive impairment. A brain MRI at 36 years showed severe 
cortical and cerebellar atrophy and diffuse periventricular hyperintensity in 
T2-weighted sequences. At age 40, the patient became wheelchair-bound 
and totally dependent on caregivers for activities of daily living. The 
patient has since developed axial hypotonia, postural tremor in the upper 
limbs, brisk deep tendon reflexes and bilateral Babinski sign associated 
with frontal release signs. Her vision is preserved.  
Her mother (case III-4) experienced tonic-clonic seizures since the age of 
25. She subsequently displayed behavioral disturbances, emotional lability 
and, from age 35, intellectual deterioration. At age 52, her mental 
deterioration accelerated rapidly, finally resulting in a clinical diagnosis of 
severe cognitive impairment. She died at the age of 56. 
Patient III-5, now 74 years old, is a woman who, at the age of 32, suffered 
a minor head trauma. At 66, she suffered a second head trauma, without 
significant consequences (brain CT was normal). At the age of 69, her 
cognition began to decline. On her most recent neurological examination, 
at the age of 73, she was confined to a wheelchair, aphasic and presented 
severe dementia. Postural tremor in the upper limbs was detected as well 
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action myoclonus and perioral dyskinesias. Reduced deep tendon reflexes, 
primitive reflexes and bilateral Babinski were also observed. 
Patient V-1, 45 years old, is a woman who has experienced occasional 
tonic-clonic seizures since age 21. At age 39, she had a head trauma with 
minor sequelae. Afterwards, she developed rapidly progressive cognitive 
decline, initially evident only in housework, but later also in social 
relationships. Her most recent neurological examination showed cerebellar 
dysarthria, occasional dysphasia with confabulation, ideomotor apraxia, 
inappropriate laughing, and urinary incontinence. A brain MRI showed 
severe cortical atrophy. 
Patient IV-1, deceased, was a man with severe dementia that had begun 
when he was 55 years old. At age 48, he had undergone a neurological 
examination because he had experienced tonic-clonic seizures. He died at 
age 67. 
No clinical records are available for patient III-6, a woman who reportedly 
had several episodes of generalized epilepsy starting at age 8 years, after a 
febrile episode. Relatives reported that she had experienced rapidly 
progressive intellectual decline culminating in frank dementia. Albeit 
presenting some gait impairment, she apparently walked autonomously 
until her death at age 50 years during an acute episode of massive 
rhabdomyolysis. 
 
 
